Format

Send to

Choose Destination
Clin Ophthalmol. 2016 Nov 24;10:2345-2361. eCollection 2016.

Vogt-Koyanagi-Harada syndrome - current perspectives.

Author information

1
Uveitis Service, Moorfields Eye Hospital, London, UK.
2
Uveitis Service, Moorfields Eye Hospital, London, UK; Department of Clinical Ophthalmology, UCL Institute of Ophthalmology, London, UK.
3
Uveitis Service, Moorfields Eye Hospital, London, UK; Department of Clinical Ophthalmology, UCL Institute of Ophthalmology, London, UK; Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.

Abstract

Vogt-Koyanagi-Harada syndrome is a cause of noninfectious panuveitis, leading to significant vision loss in many patients. It is an autoimmune disease occurring in genetically susceptible individuals and clinically presents as bilateral panuveitis with serous retinal detachments and hyperemic, swollen optic discs, which are associated with neurological and auditory manifestations. Early diagnosis and prompt and adequate treatment with immunosuppressive agents (corticosteroids and other immunosuppressive drugs) may halt disease progression and prevent recurrences and vision loss. This review summarizes the current knowledge on the variable clinical aspects of this disease, highlighting diagnostic and treatment strategies.

KEYWORDS:

corticosteroid; multifocal choroiditis; panuveitis; serous retinal detachment; starry sky; sunset glow fundus

Conflict of interest statement

The authors report no conflicts of interest in this work.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center